IMS: Mercado farmacéutico mundial $825 billion en 2010

Global growth will be 4 percent to 7 percent each year through 2013, the report released today from IMS Health, a Norwalk, Connecticut-based market research firm, said. The projection is 1 percentage point higher than IMS’s previous forecast in April. Demand for medicines in 2009 has been higher than IMS anticipated, said Murray Aitken, the senior vice president of the company’s Healthcare Insight division.

.../...

Products that now generate $137 billion in sales, including Pfizer Inc.’s cholesterol pill Lipitor, Bristol-Myers Squibb Co. and Sanofi-Aventis SA’s blood- thinner Plavix, and GlaxoSmithKline Plc’s asthma drug Seretide, are expected to face generic competition during the next five years, the IMS report said.

Ver...

Dinámicas del Mercado según IMS:

• Growth prospects in the U.S. market improve.

• Economic downturn affects markets to varying degrees.

• Impact of the innovation/patent loss imbalance dampens growth prospects.

• Pharmerging markets in aggregate sustain strong growth.

• Healthcare access and funding under intensifying pressure.